A “skinny label” is one way that a generic drug can be commercialized in the US when only a subset of the brand’s uses lose exclusivity. The recent Supreme Court decision in the Caraco case may put a spotlight on the opportunities for “skinny label” generics. The article found here describes some of the issues and possible policy implications that may be associated with an increased use of “skinny labels.”
The rise of central nervous system technologies: Trends reshaping CNS care
This article, co-authored by CRA’s Will Foster and Juliette Richards, explores how advances in artificial intelligence (AI), data collection, and connected...